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A major limitation to the translation of tolerogenic therapies to clinical transplantation is a
lack of biomarkers that can be used as surrogate measures for predicting the successful
induction of immune tolerance which would allow for the safe withdrawal of immunosup-
pression. We have used three different mouse models of donor speciﬁc tolerance to skin
grafts together with quantitative RT-PCR to search for potential biomarkers of tolerance
using criteria based on the presence or activity of regulatoryT cells and antigen presenting
cells (APCs) within grafts or lymphoid organs. We ﬁnd that signiﬁcant differences in gene
expression between tolerated and rejecting grafts are observed primarily within the grafted
skin and not systemically or in the draining lymph node. The pattern of gene expression
within long-term surviving tolerated grafts appear very similar to syngeneic grafts,with both
having low levels of T cell and APC inﬁltration and a bias toward relative over-expression
of “regulatory-associated” genes, while allografts destined for rejection show an overall
increase in both “regulatory” and “effector” cell associated transcripts.We also, however,
ﬁnd an increase in a large number of regulatory genes, of both innate and T cell origin,
even after grafting syngeneic skin. Taken together, these ﬁndings suggest that there may
be no tissue biomarkers uniquely able to predict donor antigen speciﬁc tolerance per se,
but that patterns of gene expression within tolerated grafts may be similar to those found
in self tissues recovering from an inﬂammatory insult.
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INTRODUCTION
Transplantation is now recognized as the best option for treat-
ing a variety of diseases that lead to organ failure. The success of
allogeneic transplantation has depended on the long-term use of
non-speciﬁc immunosuppressive agents, which expose the recip-
ient to a number of deleterious side effects, including infection
and cancer. In order to facilitate the application of potentially
tolerogenic therapies into clinical practice it would be helpful to
identify andmeasure appropriate biomarkers predicting tolerance
and graft acceptance. This would allow the identiﬁcation of those
individuals where tolerance has been established so enabling the
safe reduction or withdrawal of immunosuppressive agents.
Transplantation tolerance cannowbe readily induced in anum-
ber of different rodent models, and it is becoming clear that such
tolerance depends on the generation and activity of regulatory T
cells (Treg; Qin et al., 1993; Cobbold et al., 2006). A number of
different Treg populations have been described, and although we
do not fully understand how they act, there seem to be a core set
of genes whose expression is associated with regulation (Cobbold
et al., 2003). The expression of many of these core genes seem to
be linked to foxp3 expression (Sadlon et al., 2010), the “master”
transcription factor for both natural and induced Treg, and there-
fore assays for these gene transcripts or products would seem to
be primary candidates as biomarkers of tolerance. A secondary
source of tolerance biomarkers might be those associated with the
downstream action of Treg during maintenance of the tolerance
state. The mechanisms by which Treg function in vivo are still
unclear (Sakaguchi et al., 2009), but there is an emerging consen-
sus that they act, at least in part, by modulating antigen presenting
cells (APCs) from a pro-inﬂammatory to an anti-inﬂammatory or
pro-tolerogenic state (Chen, 2006; Cobbold et al., 2010). Relevant
APCs in this context may include not only the dendritic cells, but
also other MHC-II+ cells in the graft such as macrophages and
endothelial cells. Changes in the expression of a number of gene
products have been associated with pro-tolerogenic antigen pre-
sentation, such as a relative increase in negative costimulation (e.g.,
PDL1; Guleria et al., 2005), and increased enzymatic degradation
of essential amino acids (e.g., by IDO and arginase; Cobbold et al.,
2009).
Although Treg seem to be essential to induce and maintain the
tolerant state in vivo, we cannot assume that tolerance and activa-
tion/rejection behave as a binary switch between two alternative
states. Tolerance is not just the lack of lymphocyte activation or
of inﬂammation, as these can be achieved by immunosuppressive
agents that fail to tolerize. Consequently, biomarkers reﬂecting
a lack of inﬂammation may not be relevant to tolerance in the
presence of immunosuppressive agents. Treg also seem to operate
during any normal immune response, including the termina-
tion phase, and their presence alone is not sufﬁcient to predict
the development of tolerance. Indeed, many studies have shown
that biomarkers for Treg (such as foxp3) often correlate with
increasing inﬂammation and graft rejection rather than tolerance
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(Bunnag et al., 2008; Dijke et al., 2008; Huang et al., 2010), sug-
gesting that Treg may play a physiological role in containing
inﬂammation during an ongoing immune response. This suggests
that the use of any Treg-based biomarker for tolerance may well
dependonqualitative and contextual assessments, such as identify-
ing an increased ratio of regulatory to inﬂammatory components
in the context of a overall reduction in T cell and APC inﬁltration.
Preferred biomarkers would those that can be measured in
readily accessible sources, such as blood or urine. There is accumu-
lating evidence, however, that tolerance frequently depends on the
activity of regulatory T cells locally within the target organ (Graca
et al., 2002), and may not necessarily be associated with a sys-
temic hyporesponsiveness to donor antigen (Cobbold et al., 2004).
Although it may be possible to detect systemic secreted or excreted
products associated with regulation (e.g., cytokines or amino acid
metabolites), assays that depend on detecting Treg associated gene
transcripts or cell associated products might require the use of
tissue biopsies.
In this paper we investigated whether previously identiﬁed Treg
and modulated APC associated gene transcripts could be used as
biomarkers predicting tolerance in three different well character-
ized mouse skin grafting models. We found signiﬁcant differences
in gene expression within grafts such that we could distinguish
allogeneic skin that was destined for tolerance rather than rejec-
tion, but we observed no such differences when we examined the
spleen or draining lymph nodes of these recipients. Grafts des-
tined for tolerance appeared very similar in their pattern of gene
expression when compared to syngeneic grafts with both showing
a reduced level of T cell andAPC inﬁltration compared to rejecting
grafts and a relative increase of Treg andmodulatedAPCassociated
gene transcripts when compared to ungrafted, normal tail skin.
These data suggest that the mechanisms that maintain allograft
tolerance may be very similar to the local regulatory mechanisms
acting to maintain self tolerance in the face of an inﬂammatory
stimulus. This also means that there may be no unique gene sig-
nature able to form the basis of a reliable positive biomarker for
transplantation tolerance.
MATERIALS AND METHODS
MICE, SKIN GRAFTING, AND TOLERANCE INDUCTION
CBA/Ca, CBA.RAG1−/−, A1.RAG1−/−, B10.BR (all H-2k),
C57BL/6 (H-2b) mice, were bred and maintained under SPF con-
ditions in the animal facility of the Sir William Dunn School of
Pathology, Oxford, UK. All procedures were conducted in accor-
dance with the Home Ofﬁce Animals (Scientiﬁc Procedures) Act
of 1986. Tail skin was grafted on the lateral thoracic ﬂank of
recipient mice as previously described (Qin et al., 1990). Recip-
ients in the tolerant groups were given 3× 1mg each, on days
−1, +1, and +3 relative to their ﬁrst grafts, of non-depleting
monoclonal antibodies (Figure 1). A1.RAG1−/− recipients were
given CD4 (clone YTS 177.9.6) antibody alone (Cobbold et al.,
2004), B10.BR grafted CBA/Ca recipients were given the CD4
plus CD8 (clone YTS 105.18.10) antibodies (Qin et al., 1990),
and CBA/Ca recipients of C57BL/6 skin were given a cocktail
of CD4 plus CD8 plus CD154 (CD40L; clone MR1) antibodies
(Daley et al., 2008). Control recipients received either allogeneic
or syngeneic tail skin grafts without antibody treatment. After 100
days all recipients were given secondary challenge skin grafts from
the same strain as the original donor graft on the opposite ﬂank
(without any additional antibody treatment). Recipients were sac-
riﬁced on day 6 after second grafting and their spleens, draining
lymph nodes and all surviving grafts were taken for analysis
by qRT-PCR.
QUANTITATIVE REAL-TIME RT-PCR
Total RNAwas prepared from tissues or whole skin grafts using SV
Total RNA Lysis Buffer (Promega) and DNase-I treatment. cDNA
was generated using the StrataScript First Strand Synthesis System
FIGURE 1 | Outline of the experimental skin graft models used.
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(Stratagene), using random hexamer primers. Real-time RT-PCR
and analysis were performed using the ABI/PRISM 7700 sequence
detector system (Applied Biosystems) and inventoried “assay on
demand” Taqman® gene expression assays (Table 1) in a low den-
sity array (TLDA) format as recommended (Applied Biosystems).
Relative quantities (RQ) were calculated by the Ct method.
Samples that gave nodetectable signalwere assignedC t = 40. Sam-
ples were separately normalized either to a house keeping gene
(hprt1) or to genes speciﬁcally expressed in T cells (cd3g ) or APCs
(cd74). All statistical analyses were performed on log transformed
(RQ) data, although data is presented as a normal ratio between
two samples of interest. Ratios were considered statistically signif-
icant when log[ratio+ 2×(standard deviations)] were greater
than 0 (P < 0.05).
SELECTION OF MARKERS FOR T CELLS AND APCs AS INDICATORS OF
IMMUNE RESPONSES
The Taqman qRT-PCR gene transcript assays that were chosen for
analysis are shown in (Table 1). They were selected on the basis of
the following criteria: “signature genes” which were mainly those
considered a “master” transcription factors or cytokines for func-
tionally relevant T cell subsets (Th1, Th2, Tr1, Th17, and Treg);
chemokine receptors and adhesion molecules likely to be impor-
tant in any differential trafﬁcking or accumulation of T cell or
APC subsets in grafts or lymph nodes; enzymes implicated in the
consumption of essential amino acids by APCs under regulatory
conditions, mast cell genes (as mast cells have been previously
implicated in tolerance; Lu et al., 2006) and additional genes we
hadpreviously shown tobe associatedwith either regulatoryT cells
or modulated dendritic cells by serial analysis of gene expression
(Cobbold et al., 2003).
RESULTS
MOUSE MODELS OF TOLERANCE
We chose models where the only source of donor antigen was
the skin graft itself, as we have already shown that these mod-
els depend on the continued presence of Treg within the graft
for the maintenance of the tolerance state (Graca et al., 2002;
Cobbold et al., 2006). Such tolerance is deﬁned by the ability
to accept fresh donor-type skin grafts even though normal, but
systemic T cell reactivity to donor antigen generally appears to
remain intact when assayed in vitro (Cobbold et al., 1996), so
that conventional in vitro tests have not provided any useful bio-
markers in such models. All three models used the same fully
tolerance permissive CBA/Ca gene background recipients, but var-
ied in the frequency of donor antigen speciﬁc T cells from 100%
(A1.RAG transgenic recipients given syngeneicmale skin and non-
depleting CD4 antibody) to∼1% (CBA/Ca recipients given MHC
and minor mismatched C567BL/6 skin and both CD4, CD8, and
CD40L antibodies) to <<0.1% (CBA/Ca recipients given multi-
pleminormismatched B10.BR skin andCD4plus CD8 antibodies;
Figure 1). In order to compare intact grafts (on day 6 after graft-
ing) that we knew were destined to be accepted or rejected we
focused on an analysis of secondary challenge grafts in recipients
that had been previously tolerized by grafting and antibody co-
administration or that had been primed by prior skin grafting
alone.We also included a group of recipients given only syngeneic
primary and secondary skin grafts so that we could potentially dis-
tinguish antigen speciﬁc and non-antigen speciﬁc components of
any response. We also analyzed spleen and draining lymph nodes
from all these mice at the same time.
LIMITATIONS OF Foxp3 AS A POTENTIAL BIOMARKER OF TOLERANCE
We ﬁrst analyzed the differential expression of the “master” Treg
gene Foxp3 (Hori et al., 2003). No signiﬁcant differences in foxp3
between tolerant and rejecting recipients were observed in any
of the three models in the spleen or draining lymph nodes. Total
Foxp3 (whennormalized tohouse keeping genehprt1;Table 2)was
unable to distinguish between any of the challenge grafts destined
for tolerance compared to those primed for rejection (Table 2).
When Foxp3 values were normalized to the level of T cell inﬁltra-
tion, as indicated by CD3γ expression, there was some indication
that a higher proportion of T cells expressed the Treg associated
gene in the twomodels with the higher frequency of donor speciﬁc
T cells, but there was still a high degree of variation between dif-
ferent individuals in the TCR transgenic group at this time point,
particularly in the CD3γ content, which therefore failed to reach
statistical signiﬁcance. If such individual variation, either between
individuals or over time, of relevant transcripts were a general
ﬁnding this would limit their predictive value as biomarkers. The
only striking increase in Foxp3, whether normalized to hprt1 or
CD3γ, was observed when the originally long-term surviving tol-
erated allogeneic skin was compared with a similarly long-term
accepted syngeneic graft in the TCR transgenic model where all
T cells were speciﬁc for donor antigen. Therefore, Foxp3 does not
seem to reliably correlate with transplantation tolerance in these
models.
OTHER GENES THAT POTENTIALLY DISTINGUISH TOLERANT AND
REJECTING SKIN
Weperformed similar comparisons between challenge grafts given
to tolerant and primed recipients for a set of more than 150 genes
representative of the following categories: amino acidmetabolism,
signature T cell subset transcription factors, signature cytokines,
chemokine receptors, adhesion molecules, mast cell genes, and
additional genes associated with regulatory T cell subsets or mod-
ulated APCs previously identiﬁed by serial analysis of gene expres-
sion (Table 1). Surprisingly, none of the genes tested were found to
differ signiﬁcantly between tolerant, rejecting or syngeneic grafted
recipients when samples from the spleen or draining lymph node
were compared, which strongly supports the hypothesis (Cobbold
et al., 2006) that tolerance and immune regulation act primarily
within the local grafted tissue in these models. We did ﬁnd in all
three models that rejecting grafts tended to exhibit higher lev-
els, when compared to tolerated grafts, of both CD3γ and CD74
gene transcripts, when normalized to a house keeping gene such
as hprt1 (Table 3), suggesting an increased inﬁltration of T cells
and APC in grafts destined for rejection. In the MHC mismatched
model, where CD3γ and CD74 were most signiﬁcantly associated
with rejection (Table 4), the additional genes upregulated in reject-
ing grafts included Th1 related genes such as Ifng and Gzmb, the
Th2 related Il4 and Th17 inducing Il6. Some genes usually asso-
ciated with regulation were also over-expressed in rejecting grafts,
including Indo,Nos2,Arg1, Indol1, and foxp3 (as discussed earlier).
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Table 1 | Selection of genes for assay byTaqman qRT-PCR.
TaqManAssay Gene TaqManAssay Gene TaqManAssay Gene TaqManAssay Gene
Hs99999901_s1 18S10 Mm01292449_m1 Ccr103 Mm00607939_s1 Actb10 Mm00812512_m1 Prf1
Mm99999915_g1 Gapdh10 Mm00438270_m1 Ccr23 Mm00446968_m1 Hprt110 Mm00442834_m1 Gzmb7
Mm00434371_m1 Itga21 Mm01216172_m1 Ccr33 Mm00439103_m1 Gpr83 Mm00651853_m1 Stfa37
Mm00442890_m1 Itga31 Mm00438271_m1 Ccr43 Mm00727638_s1 Hig2 Mm00440646_m1 Furin7
Mm00439770_m1 Itga41 Mm01216171_m1 Ccr53 Mm00441911_m1 Cd40lg Mm00439191_m1 Gzma7
Mm00439797_m1 Itga51 Mm99999114_s1 Ccr63 Mm00497237_m1 Icosl Mm00516884_m1 Hp7
Mm00434375_m1 Itga61 Mm01301785_m1 Ccr73 Mm00516023_m1 Icam1 Mm00656886_g1 Mcpt15,7
Mm00801807_m1 Itgal1 Mm99999115_s1 Ccr83 Mm00456990_m1 Tln1 Mm00487638_m1 Cma1 (Mcpt5)5,7
Mm00442916_m1 Itgb71 Mm02528165_s1 Ccr93 Mm00802831_m1 Igf1r Mm00469310_m1 Ela27
Mm00441291_m1 Sell1 Mm99999054_s1 Cxcr33 Mm00803629_m1 Phb;Fyb Mm00435860_m1 Serpine17
Mm01204601_m1 Selplg1 Mm01292123_m1 Cxcr43 Mm00448831_s1 Sod3 Mm00438094_g1 Cd148
Mm00497118_m1 Aass2 Mm00432086_m1 Cxcr53 Mm00516004_m1 Hmox1 Mm00442346_m1 Tlr28
Mm00475988_m1 Arg12 Mm00472858_m1 Cxcr63 Mm00847448_s1 Rap1a Mm00546288_s1 Tlr58
Mm00477592_m1 Arg22 Mm00442206_s1 Xcr13 Mm00487448_s1 Fut4 Mm00446193_m1 Tlr98
Mm00500289_m1 Bcat12 Mm00432102_m1 Bmp74 Mm01330673_g1 Fut7 Mm01291777_m1 Ahr9
Mm00802192_m1 Bcat22 Mm00801778_m1 Ifng4 Mm00449152_m1 Tyrobp Mm00438095_m1 Cd3g9,10
Mm00473573_m1 Cdo12 Mm00439616_m1 Il104 Mm00438867_m1 Fcer1a5 Mm00658576_m1 Cd749,10
Mm00516688_m1 Ddc2 Mm00434169_m1 Il12a4 Mm00445212_m1 Kit5 Mm00649916_m1 Ms4a4b9
Mm00456709_m1 Hal2 Mm00439619_m1 Il17a4 Mm00451600_g1 Pth5 Mm00459296_m1 Ms4a6c9
Mm00456104_m1 Hdc2 Mm00434228_m1 Il1b4 Mm00432631_m1 Cort Mm00508099_m1 Tmem176b9
Mm00515786_m1 Il4i12 Mm00446185_m1 Il1rn4 Mm00480990_m1 Rnf128 (Grail) Mm00463324_g1 Pilra9
Mm00492586_m1 Indo2 Mm99999222_m1 Il24 Mm00802100_m1 Alox5ap Mm00652421_m1 Pilrb19
Mm00524206_m1 Indol12 Mm00444241_m1 Il224 Mm00469161_m1 Hebp1 Mm00655955_gH Pira69
Mm00500918_m1 Pah2 Mm00518984_m1 Il23a4 Mm01298628_m1 Skap1 Mm00776306_mH Klra69
Mm00451856_g1 Tdh2 Mm00445259_m1 Il44 Mm00493634_m1 Tgfbi Mm00452054_m1 Cd2749
Mm00451266_m1 Tdo22 Mm00439646_m1 Il54 Mm00457979_m1 Zbp1 Mm00435532_m1 Pdcd19
Mm00546816_m1 Tha12 Mm00446190_m1 Il64 Mm00656724_m1 Egr16 Mm00711660_m1 Cd809
Mm00493794_m1 Tph12 Mm00434305_m1 Il94 Mm00456650_m1 Egr26 Mm00444543_m1 Cd869
Mm00440485_m1 Nos22 Mm00441724_m1 Tgfb14 Mm00475164_m1 Foxp36 Mm00486849_m1 Ctla49
Mm00522563_m1 Mat1a2 Mm00436952_m1 Tgfb24 Mm00484683_m1 Gata36 Mm00514644_m1 S1pr19
Mm00506137_m1 Mat2b2 Mm00434189_m1 Il12rb14 Mm00515191_m1 Irf16 Mm00488795_m1 Clec4a2
Mm00444228_m1 Ccl203 Mm00434200_m1 Il12rb24 Mm00516431_m1 Irf46 Mm00490931_m1 Clec4n
Mm00436446_g1 Ccl63 Mm00434223_m1 Il17ra4 Mm03682796_m1 Rorc6 Mm00496572_m1 Gp49a
Mm00436450_m1 Cxcl23 Mm00439622_m1 Il1r24 Mm00443103_m1 Rora6 Mm00656925_m1 S100a9
Mm00469294_m1 Ebi33 Mm00519942_m1 Il23r4 Mm00450960_m1 Tbx216 Mm00802901_m1 Lgals3
Mm01216147_m1 Ccr13 Mm01212875_m1 Penk Mm00491292_g1 Zbtb326 (ROG) Mm00436767_m1 Spp1
1Adhesion molecule, 2Amino acid metabolism, 3 Chemokine/chemokine receptor, 4Cytokine/cytokine receptor, 5Mast cells, 6 Transcription factor, 7Protease/proteolysis,
8Receptor/immunity/defense, 9Signal transduction/immunity defence, 10Normalizing controls.
Note that none of these differences were observed in the draining
lymph nodes.
The corollary of these data is that tolerated skin grafts tended
to have a reduced inﬁltration by T cells and APCs as indicated
by CD3γ and CD74 expression, and none of the genes tested
(normalized to house keeping genes) were positively correlated
with tolerance.We therefore estimated the relative contribution of
different T cell and APC differentiation pathways by normalizing
T cell expressed transcripts toCD3γ andAPC related transcripts to
CD74. In the TCR transgenic model 5 T cell associated transcripts
were found to be signiﬁcantly over-expressed within tolerant com-
pared to rejecting grafts (Rorc, Gata3, Egr2, Rnf128, and Tgfb1;
Table 5) when normalized to CD3γ while Bmp7 was the only
over-expressed APC related gene (normalized to MHC-II invari-
ant chain, CD74). When we examined the C57BL/6→CBA/Ca
model we also observed over-expression of Rorc,Gata3, and Tgfb1
in tolerated grafts (Table 6), while Gata3 and Bmp7 were differ-
ential in the B10.BR-CBA model (Table 7). Over-expression of
the energy related genes Egr2 (Harris et al., 2004) and Rnf128
(Grail; Anandasabapathy et al., 2003) was only observed in the
TCR transgenic model where there were no non-antigen speciﬁc
T cells present to overwhelm the antigen speciﬁc signal. A variety
of amino acid catabolizing enzymes were also relatively increased
(normalized to CD74) in tolerated MHC and minors different
skin grafts (Tables 6 and 7). The tolerance associated genes in
common suggest a weak bias away from Th1 responses to Th17
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Table 2 | Foxp3 expression in grafts is not a reliable indicator of
tolerance.
Comparison Foxp3/ Foxp3/
Hprt1 ratio Cd3g ratio
B10BR→CBA Tol vs Rej challenge grafts 0.41 1
(n =4/group) Tol vs Syn challenge grafts 0.76 1.1
Tol vs Syn original grafts 2.1 1
C57BL/6→CBA Tol vs Rej challenge grafts 1.6 3.6*
(n =4/group) Tol vs Syn challenge grafts 0.8 3.2
Tol vs Syn original grafts 1.1 1
Male→A1RAG Tol vs Rej challenge grafts 0.8 5.3
(n =6/group) Tol vs Syn challenge grafts 0.6 0.9
Tol vs Syn original grafts 38.2* 25.5*
*P< 0.05, all other ratios were non-signiﬁcant.
Table 3 | Infiltration of skin grafts byT cells and APCs.
Comparison CD3g/ CD74/
Hprt1 ratio Hprt1 ratio
B10BR→CBA Rej vs Tol challenge grafts 6.1* 3.8*
(n =4/group) Tol vs Syn challenge grafts 1.4 1.2
Tol vs Syn original grafts 2.3 1
C57BL/6→CBA Rej vs Tol challenge grafts 16.6* 7.1*
(n =4/group) Tol vs Syn challenge grafts 4.2 1.8
Tol vs Syn original grafts 1.1 0.9
Male→A1RAG Rej vs Tol challenge grafts 8.3 2.6
(n =6/group) Tol vs Syn challenge grafts 8.6 2.3
Tol vs Syn original grafts 1.5 0.2
*P< 0.05, all other ratios were non-signiﬁcant.
Table 4 | Genes associated with rejection in C57BL/6→CBA (fully
allogeneic) skin grafts.
Gene Rej:Tol 2nd Rej:Tol
graft ratio lymph node
ratio
Cd3g 13.2* 1.1
Cd74 7.06* 1.05
Genes over-expressed in rejecting Indo 121.0* 0.6
compared to tolerated grafts Nos2 118.0* 1.3
normalized to Hprt1 Ifng 86.9* 1.5
Gzmb 84.0* ND
Arg1 18.5* 2.6
Il4 31.7* 0.5
Il6 27.6* 1.5
Indol1 14.8* 1.0
*P< 0.05 (n=6/group), all other ratios were non-signiﬁcant.
ND, not determined.
or NK cells (Rorc), Th2 cells (Gata3), and Treg activity (Tgfb1),
but there is little evidence of the dominant signature contain-
ing the variety of regulatory-associated genes that one might have
Table 5 | Differential gene expression in male→ female A1.RAG−/−
skin grafts.
Gene Ratio
T cell related genes over-expressed in Rorc 23.43*
tolerated compared to rejecting grafts Gata3 13.85*
(Cd3g normalized) Egr2 9.76*
Rnf128 (grail) 8.40*
Tgfb1 5.93*
Foxp3 5.32
APC related genes over-expressed in
tolerated compared to rejecting grafts
(Cd74 normalized)
Bmp7 5.01*
*P<0.05 (n=6/group), all others ratios non-signiﬁcant.
expected. Perhaps evenmore surprisingly, the secondary challenge
MHC mismatched skin grafts in tolerant recipients were almost
indistinguishable by their patterns of gene expression to equivalent
syngeneic grafts (Table 6).
This latter observation suggested two possibilities – ﬁrst, that
tolerated skin grafts, once fully accepted and healed in, no longer
require active regulation and are effectively ignored by the immune
system, or second, that both allogeneic and syngeneic skin require
similar active immune regulation tomaintain their tolerant status.
We have already shown, by transferring skin grafts to secondary
RAG1−/− recipients and subsequent depletion of Treg that toler-
ated grafts contain primed effector cells that are actively held in
check by Treg (Cobbold et al., 2006), so the ﬁrst possibility seems
unlikely. We found there were a large number of genes upreg-
ulated early during the process of skin grafting (Table 8), even
in T cell deﬁcient recipients, many of which may also have an
immunoregulatory function [e.g., Bcat1, Hdc, Arg1, Ebi3, Gzma,
Tdh, and Tmem176b (TORID)]. We then looked for additional
genes expressed by long-term surviving syngeneic skin grafts on
CBA/Ca recipients with an intact immune system compared with
freshly harvested normal tail skin we found that the syngeneic
grafts were highly enriched for Treg associated gene transcripts
(Table 9), including Foxp3, Gata3, Il10, and Zbtb32 (ROG) and
modulated APCs (IL4i1 and Nos2). This latter result may repre-
sent an ampliﬁcation of the normal bias toward regulatory T cells
that has been previously described in the skin and which has been
suggested to maintain (self) tolerance in the face of an inﬂamma-
tory stimulus (Dudda et al., 2008). In other words, it is possible
that self tolerance to certain skin antigens is also dependent on
active regulation.
DISCUSSION
Although foxp3 represents the best marker currently available for
identifying regulatory T cells, we found that it could not be used
as a reliable biomarker to indicate transplantation tolerance even
when we analyzed the grafted tissue itself. Indeed, absolute foxp3
levels were often higher in grafts undergoing rejection, as has been
previously reported (Dijke et al., 2007; Yang et al., 2007; Bun-
nag et al., 2008). One reason for this might be that foxp3 can
be transiently expressed in activated effector T cells (Wang et al.,
2007). An alternative possibility is that foxp3+ regulatory T cells
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Table 6 | Differential gene expression in C57BL/6→CBA (fully allogeneic) skin grafts.
Gene Tol:Rej 2nd Tol:Rej lymph Tolerant:syngeneic
grafts ratio nodes ratio 2nd grafts ratio
T cell genes upregulated in tolerated Ccl5 45.9* ND ND
compared to rejecting grafts Gata3 41.0* 1.3 0.66
normalized to Cd3g Rora 40.2* ND ND
Ccl20 40.1* ND ND
Rorc 29.6* 2.7 0.40
Itga6 22.5* ND ND
Itga3 18.0* ND ND
Il9 14.6* 1.4 1.74
Tgfb1 9.4* 1.0 0.91
Ccr9 7.0* ND ND
Rap1a 6.7* ND ND
APC genes upregulated in tolerated Tdh 51.2* 0.9 1.63
compared to rejecting grafts Ddc 34.8* 0.4 2.05
normalized to Cd74 Tgfb2 21.9* 1.7 0.96
Hal 16.1* 1.2 0.60
Cdo1 12.5* 2.9 1.09
Bcat2 10.8* 1.7 0.78
Bcat1 7.4* 0.8 0.67
*P< 0.05 (n=4/group), all other ratios were non-signiﬁcant.
ND, not determined.
Table 7 | Differential gene expression in B10BR→CBA (multiple
minors) skin grafts.
Gene Ratio
T cell genes over-expressed in Gata3 11.1*
tolerant compared to rejecting 2nd Tgfb1 4.3
grafts (Cd3g normalized)
APC genes over-expressed in Aass 42.7*
tolerant compared to rejecting Bmp7 11.2*
2nd grafts (Cd74 normalized) Hal 6.4*
Mcpt5 4.7*
Tdh 14.2
*P< 0.05 (n=4/group), all other ratios non-signiﬁcant.
are attracted to all sites of inﬂammation where they act to limit
immune pathology, but it is the balance of activation vs regulation
that determines the eventual outcome of rejection or tolerance,
respectively. One way to estimate this balance would be to nor-
malize the foxp3 expression for the number of T cells present, but
this approach was still unable to provide a clear correlation with
graft outcome, suggesting that the numbers of effector and reg-
ulatory T cells within a graft may be closely coupled and ﬁnely
balanced.
There are two ﬁndings from this study that suggest that it
may not be possible to identify biomarkers that uniquely iden-
tify tolerance in recipients of allografts. First, the only signiﬁcant
differences in gene expression between tolerated, rejecting and
syngenic responses were observed within the grafted organ itself,
and not in draining lymph nodes or spleens. This may be due
to alloantigen speciﬁc T cells preferentially accumulating at the
main site of antigen, i.e., within the graft itself (Graca et al.,
2002; Cobbold et al., 2004). In order to observe donor speciﬁc
tolerance associated biomarkers systemically it may be necessary
for the alloantigen to also be systemically distributed, as may be
seen, for example, in some liver transplant recipients that develop
macrochimerism (Starzl et al., 1992), by inducing tolerance by
chronic administration of soluble peptide antigen (Apostolou and
von Boehmer, 2004), or by providing a systemic alloantigen boost
to enrich Treg in the lymphoid tissues (Bemelman et al., 1998).
Second, the pattern of gene expression that distinguished toler-
ated from rejecting grafts, i.e., a reduced inﬂammatory inﬁltrate
and a bias toward regulatory T cell andAPC associated transcripts,
was indistinguishable from that seen in syngeneic grafts (except in
the TCR transgenic model where all T cells were donor antigen
speciﬁc).
Although a lack of inﬂammation in tolerated grafts is an
important observation, it may not represent a useful predictive
biomarker in the context of clinical transplantation at the point
where the recipients are still on high doses of immunosuppressive
and anti-inﬂammatory drugs. The similarity between tolerated
allografts and syngeneic grafts also suggests that transplantation
tolerance is probably maintained by the same mechanisms that
are actively maintaining self tolerance in normal peripheral tis-
sues. While allo-tolerance is being maintained, at least in part,
by an antigen speciﬁc regulatory T cell population (as observed
in the monospeciﬁc TCR transgenic model), in a recipient with
an intact polyclonal repertoire the frequency of allospeciﬁc reg-
ulatory cells, even within grafts, will likely be too low to provide
a distinct and detectable gene signature above the background
of regulation mediated by innate and self reactive components.
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Table 8 | Genes over-expressed in skin during the process of grafting
and in the absence of adaptive immunity.
Gene Ratio
Genes upregulated in skin during Spp1 83.8*
the process of grafting in the Bcat1 52.4*
absence of adaptive immunity Il1b 39.3*
(Hprt1 normalized) Clec4a2 30.2*
Ms4a6c 27.6*
Gp49a;Lilrb4 20.9*
Tyrobp 19.1*
Pilra 18.5*
Clec4n 17.3*
Zbp1 13.5*
Ccr1 12.6*
Hdc 11.6*
Cd80 10.8*
Arg1 10.4*
Ccr7 8.7*
Pira6 8.3*
Cd86 8.3*
Ebi3 7.9*
Hp 7.9*
Gzma 6.2*
Mcpt5 6.1*
Tlr2 5.2*
Alox5ap 4.9*
Ms4a4b 4.4*
Tdh 4.1*
Tmem176b 4.1*
Irf1 3.8*
Ccl6 3.7*
Hmox1 3.5*
Foxp3 0.5
Cd3g 0.5
CD74 1.5
*P< 0.05 (n=4/group), other ratios non-signiﬁcant.
This background response to syngeneic grafts may be very simi-
lar to the normal process of limiting an inﬂammatory or healing
response throughout the body, so any systemically detectable toler-
ance associated gene products may be uninformative with respect
to the state of the allograft.
A detection of systemic regulatory gene products may,
however, provide some indication of whether a particular
Table 9 | Syngeneic skin grafts over-express genes associated with
regulatory cells.
Gene Ratio
Genes over-expressed in syngeneic Foxp3 40.1*
original grafts vs normal skin (Hprt1 Il4i1 17.1*
normalized)+ Zbtb32(ROG) 13.0*
Nos2 4.7*
Il10 4.7*
Gata3 3.3*
*P<0.05 (n=4/group).
+This table excludes all genes listed inTable 8 as over-expressed in the absence
of adaptive immunity.
immunosuppressive regimen is permissive rather than inhibitory
of immune regulatorymechanisms in general. Publishedbiomark-
ers [from“Reprogramming the Immune System for Establishment
of Tolerance” (RISET) and “International Tolerance Network”
(ITN) Turka et al., 2010] may therefore be more indicative of the
systemic responses of individual patients to immunosuppressive
agents and the type of graft they received than tolerance to the
graft alloantigens per se.
We used skin grafts throughout these experiments as these rep-
resent our most robust and well characterized model systems of
donor antigen speciﬁc tolerance that is completely dependent on
the presence of Tregs within the tolerated tissue (Graca et al., 2002;
Cobbold et al., 2006), but it is possible that the vascularized organ
graftsmost often used clinicallymay differ from skin grafts, partic-
ularly in their initial healing and angiogenic responses. Skin grafts,
however, are already re-vascularized by day 4, and we found that
tolerated allografts were similar in their regulatory gene signature
to syngeneic grafts at both 6 and+100 days post grafting,when any
initial vascularization, wound healing and ischemic reperfusion
responses would have resolved. We would therefore have no rea-
son to expect that our ﬁndings from skin grafting would differ, in
general terms, to the transplantation of vascularized organs.
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